Multicriteria neutrosophic method for estimating biomarkers in head injury

Abstract

More than two decades ago, the criteria for an optimal biomarker in traumatic brain injury were outlined and defined as one with high specificity and sensitivity to brain tissue, released only after irreversible injury, rapidly detectable in cerebrospinal fluid and peripheral blood; it reflects the severity and extent of the injury in a temporally predictable manner. Direct sampling of injured brain tissue is not feasible, although it would be the most informative source; other biological fluids are subject to factors such as biomarker release, the blood-brain barrier and dilution in systemic circulation. Although there are still no clinically validated biomarkers for the diagnosis of acute brain injuries, various research studies have highlighted the potential of many of them, the most studied being neuron-specific enolase and S100B protein. Given the promising future that biomarkers offer in the early treatment of traumatic brain injury and the prevention of its complications, the aim of the research is to develop a multicriteria neutrosophic method to estimate biomarkers in traumatic brain injury.